Back to top

Analyst Blog

OncoGenex Pharmaceuticals, Inc. (OGXI - Snapshot Report) recently announced that it is looking to move its oncology candidate, OGX-427, into a phase II study (Cedar: n~140). The study will evaluate OGX-427 as a first-line therapy in patients suffering from advanced squamous cell lung cancer.

The investigator-sponsored, randomized, open label phase II study will investigate whether progression-free survival (PFS) outcomes can be improved by adding OGX-427 to Eli Lilly & Company’s (LLY - Analyst Report) Gemzar and Bristol-Myers Squibb Company’s (BMY - Analyst Report) Paraplatin.

In the Cedar study, patients will be randomized to receive either OGX-427 plus Gemzar and Paraplatin therapy, or Gemzar and Paraplatin therapy alone.

Cedar is the second randomized phase II study being conducted with OGX-427 in advanced lung cancer.

Cedar is however the seventh phase II study being conducted with OGX-427 after Borealis-1, Borealis-2, Pacific, Spruce, OGX-427-PR01 and Rainier.

The Borealis-1 study is designed to evaluate the survival benefit, safety and tolerability of combining OGX-427 with gemcitabine and cisplatin in the first-line treatment of patients with advanced bladder cancer. OncoGenex expects to complete patient enrolment in the second half of 2013.

The Borealis-2 study is being conducted in patients suffering from advanced or metastatic bladder cancer whose disease has progressed following initial platinum-based chemotherapy treatment.

The Pacific study is evaluating the benefit of OGX-427 plus Zytiga in patients with castrate- resistant prostate cancer (CRPC). It is currently enrolling patients.

The Spruce study is being conducted for the treatment of previously untreated advanced non-squamous non-small cell lung cancer patients. OncoGenex expects to start patient enrolment later in 2013.

OGX-427-PR01 is evaluating the benefit of OGX-427 plus prednisone. in CRPC patients. Rainier is designed to evaluate the survival benefit of adding OGX-427 to Abraxane plus Gemzar in previously untreated metastatic pancreatic cancer patients. Patient enrollment is expected to begin in mid-2013.

OncoGenex carries a Zacks Rank #2 (Buy). Currently, Santarus, Inc. looks more attractive with a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
CENTURY ALU… CENX 22.53 +4.50%
ERBA DIAGNO… ERB 2.91 +4.30%
PLANAR SYST… PLNR 4.31 +3.86%
MALLINCKROD… MNK 72.17 +3.83%
GTT COMMUNI… GTT 12.06 +3.52%